YT-19/22
/ BriSTAR Immunotech
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
September 28, 2022
CD19/CD22-Dual-STAR-T for Patients With B Cell Acute Leukemia(B-ALL)
(clinicaltrials.gov)
- P1 | N=2 | Terminated | Sponsor: Hebei Yanda Ludaopei Hospital | N=12 ➔ 2 | Trial completion date: Dec 2022 ➔ May 2022 | Suspended ➔ Terminated | Trial primary completion date: Oct 2022 ➔ May 2022; Adjustment plan
Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Hematological Malignancies • Leukemia • Oncology • CD19 • CD22
February 14, 2022
CD19/CD22-Dual-STAR-T for Patients With B Cell Acute Leukemia(B-ALL)
(clinicaltrials.gov)
- P1 | N=12 | Suspended | Sponsor: Hebei Yanda Ludaopei Hospital | Recruiting ➔ Suspended
Trial suspension • Hematological Malignancies • Leukemia • Oncology • CD19 • CD22
June 07, 2021
CD19/CD22-Dual-STAR-T for Patients With B Cell Acute Leukemia(B-ALL)
(clinicaltrials.gov)
- P1; N=12; Recruiting; Sponsor: Hebei Yanda Ludaopei Hospital; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open • Hematological Malignancies • Leukemia • Oncology • CD19 • CD22
August 11, 2020
CD19/CD22-Dual-STAR-T for Patients With B Cell Acute Leukemia(B-ALL)
(clinicaltrials.gov)
- P1; N=12; Not yet recruiting; Sponsor: Hebei Yanda Ludaopei Hospital
Clinical • New P1 trial • Hematological Malignancies • Leukemia • Oncology
1 to 4
Of
4
Go to page
1